IL1B and neoplasm: Recent evidence has also shown that the nature of tumor cells, in particular their low or high aggressiveness, dictates the type of interactions with MSCs and notably the production of multiple chemokines and prostaglandin E2 upon release of IL-1β by tumor cells.